Summary of cold-evoked behavioral shifts following UV injury in <i>Drosophila</i> larvae. by Heather N. Turner (6157268)

Dependence of UV-Induced cold-evoked behaviors on temperature. by Heather N. Turner (6157268)

Non-hydrolysable ATP analogues prevent decrease of I_Ca,L by metabolic inhibition. by Giedrius Kanaporis (4405525)

<i>Brv1</i> is involved in the UV-induced shift of behavioral responses to cold. by Heather N. Turner (6157268)

Diverse stress conditions trigger a rapid and dramatic decrease in miR-520b-3p and a corresponding increase in ATF5 mRNA over time in HeLa cells. by Kari A. Gaither (9046190)

The UV-induced switch of cold-evoked behaviors requires class IV and Ch peripheral sensory neurons. by Heather N. Turner (6157268)

Injury-induced cold sensitization in <i>Drosophila</i> larvae involves behavioral shifts that require the TRP channel Brv1 by Heather N. Turner (6157268)

“…Under baseline, non-injured conditions larvae primarily produce a CT response to an acute cold (10°C) stimulus, however, we show that cold-evoked responses shift following tissue damage: CT responses decrease, US responses increase and some larvae exhibit a lateral body roll (BR) that is typically only observed in response to high temperature and noxious mechanical stimuli. …”

UV irradiation does not alter cold-evoked calcium responses. by Heather N. Turner (6157268)

Gene list of non-identical regions of annotated pHCM2 plasmid sequence of <i>S</i>. Paratyphi A and <i>S</i>. Java isolated from Bangladesh and to the reference pHCM2 plasmid. by Sadia Isfat Ara Rahman (8501859)

Cut-point analysis using Youden’s J Index. by Dandan Gong (5744666)

“…The optimal cut-off point of the CD4⁺ count was 50 Nr/μl or less. …”

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Depleted antibody secreting cells did not result in decreased donor specific antibody in non-sensitized animals. by Natalie M. Bath (6316517)

“…Data analyzed using ANOVA. (A) T (CD3⁺) and (B) B (CD45R⁺) cell flow crossmatch was performed in non-sensitized animals. …”

The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of non-caloric saccharin solution. by Pia Steensland (362091)

Table_1_A point mutation in MC06g1112 encoding FLOWERING LOCUS T decreases the first flower node in bitter gourd (Momordica charantia L.).xlsx by Jian Zhong (329110)

“…A point mutation (C277T) in MC06g1112, which results in a P93S amino acid mutation between parental lines, may be responsible for decreasing FFN in bitter gourd. …”

The global transcription is decreased in VBNC but remains specific. by Benjamin Hommel (523072)